Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

IPCA Labs

Pharmaceutical intelligence for IPCA Labs with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Assets
2

Recent signals(2)

StrategyJuly 26, 2026

FDA Grants AP Status for Alendronate Sodium ANDA206387 by IPCA Labs

The FDA has granted approval status (AP) for the ANDA206387 application for Alendronate Sodium submitted by IPCA Labs.

RegulatoryJuly 12, 2026

FDA Approves ANDA203103 for Propranolol Hydrochloride by IPCA Labs

The FDA has approved ANDA203103 for Propranolol Hydrochloride submitted by IPCA Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryJuly 12, 2026

FDA Approves ANDA203103 for Propranolol Hydrochloride by IPCA Labs

The FDA has approved ANDA203103 for Propranolol Hydrochloride submitted by IPCA Labs.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

FDA →
Propranolol Hydrochloride →

Therapeutic areas

Beta Blocker →
Bisphosphonate →
Bone Health →
Cardiovascular →
Cardiovascular · Beta Blocker →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.